In a filing, Design Therapeutics Inc revealed its Director Prasad Deepa unloaded Company’s shares for reported $23864.0 on Dec 18 ’24. In the deal valued at $6.27 per share,3,806 shares were sold. As a result of this transaction, Prasad Deepa now holds 20,000 shares worth roughly $0.12 million.
Then, William Arsani sold 814,874 shares, generating $3,463,214 in total proceeds. Upon selling the shares at $4.25, the Director now owns 0 shares.
Before that, Logos SPV 1 LP bought 814,874 shares. Design Therapeutics Inc shares valued at $3,455,066 were divested by the Director at a price of $4.24 per share.
Piper Sandler upgraded its Design Therapeutics Inc [DSGN] rating to an Overweight from a a Neutral in a research note published on May 07, 2024; the price target was increased to $12 from $6. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who decreased its forecast for the stock in mid November from “an Overweight” to “a Neutral”. Wedbush also remained covering DSGN and has decreased its forecast on August 15, 2023 with a “Neutral” recommendation from previously “an Outperform” rating. SVB Securities revised its rating on August 15, 2023. It rated DSGN as “a Market perform” which previously was an “an Outperform”.
Price Performance Review of DSGN
On Friday, Design Therapeutics Inc [NASDAQ:DSGN] saw its stock jump 4.34% to $6.25. Over the last five days, the stock has gained 11.61%. Design Therapeutics Inc shares have risen nearly 135.85% since the year began. Nevertheless, the stocks have risen 143.19% over the past one year. While a 52-week high of $7.77 was reached on 11/13/24, a 52-week low of $2.24 was recorded on 02/13/24. SMA at 50 days reached $5.88, while 200 days put it at $4.63.
Levels Of Support And Resistance For DSGN Stock
The 24-hour chart illustrates a support level at 5.95, which if violated will result in even more drops to 5.64. On the upside, there is a resistance level at 6.47. A further resistance level may holdings at 6.68. The Relative Strength Index (RSI) on the 14-day chart is 52.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.18, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 42.33%. Stochastics %K at 47.80% indicates the stock is a holding.
How much short interest is there in Design Therapeutics Inc?
A steep rise in short interest was recorded in Design Therapeutics Inc stocks on 2024-11-29, growing by 0.12 million shares to a total of 2.71 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 2.59 million shares. There was a rise of 4.49%, which implies that there is a positive sentiment for the stock.
